Madrigal (MDGL)
NASDAQ:MDGL
Want to see MDGL full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-2.39Last Year’s EPS
-1.9Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.Company Guidance
Blockbuster Net Sales and Strong Quarterly Revenue
Trailing 12-month net sales for Rezdiffra exceeded $1.1 billion. First quarter 2026 net sales were $311.3 million, representing year-over-year growth of 127%.
Rapid Patient Growth and Expanding Addressable Market
Active patients on Rezdiffra exceeded 42,250 at quarter end, a ~2.5x increase year-over-year. U.S. addressable diagnosed F2/F3 population expanded from ~315,000 (end 2023) to ~460,000 (end 2025), an increase of ~46% (described as nearly 50%).
Pipeline Expansion — siRNA Addition and >10 Programs
Pipeline now includes more than 10 programs and the in‑license of ARO‑PNPLA3 (clinical‑stage siRNA). ARO‑PNPLA3 Phase I showed up to a 46% reduction in liver fat at 12 weeks (single dose) in the genetically defined PNPLA3 homozygote population (~30% of F2–F3 patients are homozygous carriers).
Progress on Outcomes Trials with Clear Milestones
Rezdiffra is running an event‑driven F4C outcomes trial expected to read out in 2027 and a F2/F3 histology‑driven Phase III with data expected in 2028. Open‑label data showed 65% of patients with clinically significant portal hypertension (CSPH) shifted into lower‑risk categories by year 2, supporting the F4C program.
Commercial Execution, Prescriber Breadth and Real‑World Evidence
More than 10,000 prescribers; established first‑line payer access; strong real‑world feedback across multiple endpoints (liver stiffness, MRI‑PDFF, enzymes, LDL‑C, Lp(a)). Company reported best MBRx week last quarter and best NBRx month since launch in April; >40 Rezdiffra abstracts presented at meetings.
Solid Financial Resources to Support Growth
Ending cash, cash equivalents, restricted cash and marketable securities of $817.9 million, providing runway to support launch, pipeline advancement and ongoing business development.
MDGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $502.47 | $539.73 | +7.42% |
Feb 19, 2026 | $491.49 | $436.87 | -11.11% |
Nov 04, 2025 | $412.35 | $444.64 | +7.83% |
Aug 05, 2025 | $312.11 | $338.91 | +8.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Madrigal (MDGL) report earnings?
Madrigal (MDGL) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Madrigal (MDGL) earnings time?
Madrigal (MDGL) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDGL EPS forecast?
MDGL EPS forecast for the fiscal quarter 2026 (Q2) is -2.39.